肿瘤药学Issue(2)：133-135,153,4.DOI:10.3969/j.issn.2095-1264.2013.032
吉西他滨联合奥沙利铂治疗胰腺癌的疗效观察
Observation on the Therapeutic Effect of Gemcitabine Combined with Oxaliplatin in the Treatment of Pancreatic Cancer
李晋生 1刘丽娜 2马好霞 1张芳 1杨浩浩1
作者信息
- 1. 晋城市人民医院肿瘤治疗科，山西 晋城，048000
- 2. 济源职业技术学院护理系，河南 济源，459000
- 折叠
摘要
Abstract
Objective To study the clinical efficacy and safety of gemcitabine combined oxaliplatin in the treatment of pancreatic cancer and provide references for the further clinical application. Methods 58 cases of pancreatic cancer patients admitted in our hospital from August 2010 to June 2011were randomly divided into two groups (29 cases in each group). The control group was treated by gemcitabine, while the observation group was given gemcitabine combined oxaliplatin. The objective response rate, adverse reaction and survival period were compared between the two groups. Results The objective response rate of observation group was 96.6% (28/29), which was significantly higher than that of the control group (79.3%, P<0.05). The clinical benefit rate of observation group was 75.9% (22/29), which was also significantly higher than that of the control group (58.6%, P<0.05). The incidence rate of adverse reactions of the observation group was significantly lower than that of the control group (P<0.05). The average survival time of observation group was 6.8±1.3 years, which was obviously longer than that of the control group (2.3±1.1) (P<0.05). Conclusion Compared with treatment with Gemcitabine alone, Gemcitabine combined with oxaliplatin may effectively improve the objective response rate, prolong the survival period, and reduce the adverse reaction of patients with pancreatic cancer. It is worth of clinical application.关键词
吉西他滨/奥沙利铂/胰腺癌/临床效果/不良反应Key words
Gemcitabine/Oxaliplatin into/Pancreatic cancer/Clinical effect/Safety分类
医药卫生引用本文复制引用
李晋生,刘丽娜,马好霞,张芳,杨浩浩..吉西他滨联合奥沙利铂治疗胰腺癌的疗效观察[J].肿瘤药学,2013,(2):133-135,153,4.
